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Abstract
Background: An attempt was made to reprogram peripheral blood cells into human induced pluripotent stem cell
(hiPSCs) as a new cell source for cartilage repair.
Methods: We generated chondrogenic lineage from human peripheral blood via hiPSCs using an integration-free
method. Peripheral blood cells were either obtained from a human blood bank or freshly collected from volunteers.
After transforming peripheral blood cells into iPSCs, the newly derived iPSCs were further characterized through
karyotype analysis, pluripotency gene expression and cell differentiation ability. iPSCs were differentiated through
multiple steps, including embryoid body formation, hiPSC-mesenchymal stem cell (MSC)-like cell expansion, and
chondrogenic induction for 21 days. Chondrocyte phenotype was then assessed by morphological, histological and
biochemical analysis, as well as the chondrogenic expression.
Results: hiPSCs derived from peripheral blood cells were successfully generated, and were characterized by
fluorescent immunostaining of pluripotent markers and teratoma formation in vivo. Flow cytometric analysis
showed that MSC markers CD73 and CD105 were present in monolayer cultured hiPSC–MSC-like cells. Both alcian
blue and toluidine blue staining of hiPSC–MSC-chondrogenic pellets showed as positive. Immunohistochemistry of
collagen II and X staining of the pellets were also positive. The sulfated glycosaminoglycan content was significantly
increased, and the expression levels of the chondrogenic markers COL2, COL10, COL9 and AGGRECAN were
significantly higher in chondrogenic pellets than in undifferentiated cells. These results indicated that peripheral
blood cells could be a potential source for differentiation into chondrogenic lineage in vitro via generation of
mesenchymal progenitor cells.
Conclusions: This study supports the potential applications of utilizing peripheral blood cells in generating seed
cells for cartilage regenerative medicine in a patient-specific and cost-effective approach.
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Background
Articular cartilage has a very poor intrinsic capacity for
self repair, which poses a problem for regenerative
medicine. Cartilage tissue engineering is a promising
and potential directive to provide biological replace-
ment tissue. This may require an adequate amount of
seed cells and, as it is generally known, there is a limited
source of naturally occurring autologous chondrocytes.
Seed cells usually obtained from an ectopic cartilage
source often require additional surgery which seems to
be a significant challenge in clinical practice [1]. Adult
stem cells appear to be a promising alternative cell
source for cartilage tissue engineering; nevertheless, it is
undoubtedly fraught with limitations. The percentage of
mesenchymal stem cells (MSCs) in the bone marrow of
an adult is rather low, and the yield of stem cells from
older patients has also been reported to show relatively
lower proliferative rates in culture. Some comorbidities
may also affect the proliferative abilities of stem cells.
Previous studies have postulated that MSCs from
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patients with osteoarthritis potentially show reduced
chondrogenic differentiation [2].
Recently, human induced pluripotent stem cells (hiPSCs)
generated from somatic cells established an innovative dir-
ection for cartilage repair. This basically introduces OCT3/
4 and SOX2 along with either KLF4, c-MYC, NANOG, or
LIN28 through viruses [3, 4]. Similar to embryonic stem
cells, hiPSCs have pluripotency, proliferation capacity and
gene expression without known ethical dilemma limita-
tions. Moreover, new methods for generating iPSCs without
viral vectors have also been developed in order to mitigate
tumorigenicity [5, 6]. In addition to cell-based therapeutic
applications, iPSC technology could also provide patient-
specific cells and tissue models for tissue repair [7]. This
may help overcome limitations associated with current cell
harvest sources.
Many kinds of cells have been used to generate iPSCs.
However, the most common somatic cells that have been
extensively studied are fibroblasts which have been
deeply explored for their possible reprogramming poten-
tials; nevertheless, they possess some limiting properties.
One of the limiting properties of primary fibroblasts in-
cludes the need for expansion into several passages in
vitro, making it a questionable source for generating
patient-specific stem cells [8]. An easy tendency for mu-
tation may hinder the progress of application and further
studies. Recently, umbilical cord blood and peripheral
blood cells (PBCs) were found to be advantageous har-
vest sources for reprogramming. PBCs are commonly
utilized in clinical applications and are scientifically and
abundantly stored. PBCs are considered to be an ideal
source, which might redirect focus of the research away
from the skin to the blood. Zhang discovered efficient
ways to generate iPSCs from human PBCs which makes it
more accessible [9]. Recently, umbilical cord blood cells
have been reported to be induced for differentiation into
cardiac cells (cardiomyocytes) and hepatocytes [10, 11].
However, there is relatively scarce information on PBC re-
programming and differentiation into chondrocytes.
In this current study, we utilized PBCs as a source by
reprogramming these cells to differentiate into chondro-
genic lineage with a combination of a pellet culture sys-
tem to mimic chondrocyte formation.
Methods
Blood sample and ethics statement
The use of human peripheral blood was approved by the
Institutional Review Board (IRB). The IRB or Ethics
Committee of Beijing Chao-Yang Hospital approved this
study. The participants provided their written informed
consent to participate in the study. The ethics committees
or IRBs of Beijing Chao-Yang Hospital approved this
consent procedure. This study was performed in accord-
ance with the guidelines of the Animal Care and Use
Committee of the National Institute of Biological Sciences
and with the Guide for the Care and Use of Laboratory
Animals. PBCs were either obtained from a blood bank or
were freshly collected from volunteers. Peripheral blood
mononuclear cells (PBMNCs; lymphocytes and mono-
cytes) were obtained by density gradient centrifugation
with Ficoll-paque plus (GE) at room temperature. The age
of the healthy donors (male or female) ranged from 20–40
years. The human mesenchymal stem cells (hMSCs) were
derived and donated by Dr. Xia [12].
Generating integration-free hiPSCs and hiPSC culture
The human episomal vectors pEV SFFV-OS (OCT4-2a-
SOX2), pEV SFFV-MK (MYC-2a-KLF4), and pEV SFFV-B
(BCL-XL) were kindly donated by Dr. Xiao-Bing Zhang.
PBMNCs were cultured for 5 days before nucleofection.
To generate integration-free iPSCs, cells were nucleo-
fected with 20 μg EV plasmid DNA (10 μg OS + 5 μg
MK + 5 μg BCL-XL). PBMNCs (1.5 × 106) were nucleo-
fected by Amaxa Nucleofector® Program U-008 (Lonza)
and then seeded into a 35-mm dish preseeded with
feeder. The first colonies appeared at days 10–14 after
coculture of PBMNCs with feeder. The number contin-
ued to increase. About 25 iPSC colonies were selected
for further culture. The hiPSC medium was composed
of knockout Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen) supplemented with 15 % knockout
serum replacement (KSR; Invitrogen), 5 % fetal bovine
serum (FBS; Hyclone), 1 × nonessential amino acids
(Invitrogen), 0.1 mM β-mercaptoethanol (Invitrogen),
1 mM L-glutamine (Invitrogen), and 8 ng/ml basic
fibroblast growth factor (bFGF; Peprotech). iPSCs were
passaged every 4–6 days by treatment with dispase
(Invitrogen). After 10 passages, iPSCs were further char-
acterized through karyotype analysis, pluripotency gene
expression and cell differentiation ability (embryoid
body (EB) and teratoma formation) examination.
Karyotype analysis
One day after human iPSCs were subcultured, the cells
were exposed to 0.25 μg/ml colcemid for 3.5 hours,
digested, collected, and exposed to a hypotonic solution
(0.4 % sodium citrate:0.4 % KCl = 1:1) for 16 minutes.
The cells were fixed twice with methanol/acetic acid
(3:1) for 1 hour in total. Then the cells were dropped
onto cold, wet and clean glass slides. The slides were in-
cubated for 4 hours at 70 °C. Then the slides were
treated with 0.01 % trypsin at 37 °C for 10–12 seconds
and washed with 0.9 % NaCl and then stained with
Giemsa solution (Giemsa:phosphate buffer = 1.5 ml:40 ml,
pH 7.4) at 37 °C for 2.5 minutes. The karyotype was de-
termined by microscopic examination. More than twenty
chromosomal spreads were counted per population.
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Immunocytochemical analysis
Colonies were fixed for 2 hours at room temperature with
4 % paraformaldehyde and then incubated at room
temperature for 15 minutes with 1 % Triton X-100/phos-
phate-buffered saline (PBS). Cells were washed three times
in PBS and blocked at 37 °C for over 3 hours with 4 %
normal goat serum (Chemicon). Subsequently, cells were
incubated at 4 °C overnight with primary antibody to
Oct4 (1:500, Santa Cruz), SSEA4 (1:500, Life Technology),
Nanog (1:500, Bethyl laboratories), TRA-1-60 (1:250, Life
Technology), and TRA-1-81 (1:250, Life Technology).
Cells were washed three times in PBS and incubated at
37 °C for 2 hours with goat anti-rabbit Alexa-Flour
594-conjugated (Life technologies) and goat anti-mouse
Alexa-Fluor 488-conjugated (Life Technology) secondary
antibodies (1:500 in 1 % normal goat serum in PBS). Un-
bound secondary antibodies were removed in three
washes with PBS. Nuclei were identified by 1 μg/ml DAPI
(Invitrogen) staining at room temperature for 5 minutes.
Images were acquired using a confocal laser scanning
microscope (LSM 510 META; Carl Zeiss).
In vitro and in vivo differentiation
In vitro differentiation was performed by the EB forma-
tion method. The undifferentiated hiPSC colonies were
manually dissected into smaller pieces using a fire-
drawn glass needle. They were cultured in nonadherent
petri dishes containing hiPSC medium without bFGF.
EBs were characterized by the pieces of colonies taking
on a round appearance, with smooth borders. Some ir-
regularly shaped but smooth-bordered EBs may be sev-
eral EBs clustered together.
In vivo differentiation was established by formation of
teratomas and examined by hematoxylin and eosin stain-
ing. The undifferentiated hiPSC colonies from a conflu-
ent 60-mm dish were manual dissected into smaller
pieces. Cells were suspended in 200 μl PBS containing
2 % KSR and were injected under the inguinal skin of
SCID mice. After 7–8 weeks the teratomas were excised
and fixed in 10 % neutral buffered formalin for 24 hours.
Dehydration was performed with graded ethanol
series followed by three consecutive steps of clarifi-
cation in xylene and paraffin-embedment during
tissue processing. Approximately 5 μm adjacent sec-
tions were made using a microtome. The slides
were allowed to dry overnight at 42 °C. Deparaffini-
zation was performed in two cycles using xylene.
Decreasing alcohol series were used for rehydration,
followed by a final rinse with deionized water for
5 minutes. Hematoxylin solution was added to the
tissue for 1 minute. The sections were stained blue
in NaOH until the nuclei stained bluish-purple and
detected under microscopy. Sections were placed in
deionized water for 3 minutes after being washed in
distilled water. Dehydration was performed with
graded ethanol series. Eosin solution was added to
the tissue for 1 minute. Dehydration was performed
with 100 % EtOH followed by clarification with xy-
lene. The slides were mounted with resinous mount-
ing medium and visualized under a microscope.
Cell pellet formation and chondrocyte differentiation
The undifferentiated hiPSC colonies were manually dis-
sected into smaller pieces and cultured for 10 days in non-
adherent petri dishes containing hiPSC medium without
bFGF for EB formation. Approximately 25 % of the initial
media was replaced with an equal amount of the differen-
tiation media (DMEM, 20 % FBS, 1 × non-essential amino
acids, 0.1 mM β-mercaptoethanol, 1 mM L-glutamine)
every 2 days. EBs were then seeded onto 10 cm gelatin-
coated dishes. Within 10 days of cellular confluence, the
cells were incubated with 0.25 % trypsin/EDTA at 37 °C
for 5 minutes, and reseeded on new gelatin-coated dishes.
At 90–100 % confluence of cells, which is often observed
in 5 to 7 days, the cells were harvested with 0.25 % tryp-
sin/EDTA. The cells were sorted by CD73 and CD105
double positivity. Then they (3 × 105) were placed in a
15-ml polypropylene tube, centrifuged at 1200 rpm for
3 minutes at room temperature, and resuspended in
chondrogenic differentiation medium (DMEM-HG sup-
plemented with 10 % ITS (Invitrogen), 10−7 M dexa-
methasone, 1 mM ascorbate-2-phosphate (Invitrogen),
1 % sodium pyruvate (Invitrogen), and 10 ng/ml trans-
forming growth factor-beta 1 (Peprotech)). The cells
were recentrifuged and maintained in small pellet form
for 21 days. The culture medium was replaced every
3 days. The hMSCs were also collected and cultured in
this chondrogenic differentiation medium for 21 days.
Flow cytometry analysis
Before cells were placed in a 15 ml polypropylene tube,
the cell populations acquired a homogenous, fibroblast-
like morphology. The iPSC–MSC-like cells were grown
to attain confluence, harvested by 0.25 % trypsin/EDTA,
washed with PBS, and resuspended in staining buffer
consisting of 2 % FBS in PBS. Cell suspensions were
mixed with PE mouse anti-human CD73, APC mouse
anti-human CD105, APC mouse anti-human CD45 and
PE mouse anti-human CD34. The isotype controls used
were mouse IgG1 K isotype control APC and mouse
IgG1 K isotype control PE, which were appropriate iso-
types related to antibodies (eBioscience) in our experi-
ments. Samples were run on a LSR II Flow Cytometer
(BD Biosciences) instrument. For each analysis, a mini-
mum of 10,000 cells were assayed. hMSCs were also
used as a positive control and detected.
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Histological analysis of chondrogenic differentiation
Chondrogenic differentiation was assessed by alcian blue
and toluidine blue staining of pellet sections. The aggre-
gates were fixed in 10 % neutral-buffered formalin for
24 hours. Dehydration was performed with graded etha-
nol series followed by three consecutive steps of clarifi-
cation in xylene and paraffin-embedment during tissue
processing. Approximately 4-μm adjacent sections were
made using a microtome. The slides were allowed to dry
for 2 hours at a temperature of 60 °C. Deparaffinization
was performed over three cycles using xylene. Decreas-
ing alcohol series were used for rehydration, followed by
a final rinse with deionized water for 5 minutes. The
sections were then stained with 0.1 % alcian blue reagent
or 1 % toluidine blue staining for 4–5 hours and were
rinsed with distilled water. Dehydration was performed
with graded ethanol series followed by three consecutive
steps of clarification in xylene and the slides were
mounted in Permount® (Fisher) and visualized under a
microscope. Additional chondrogenic differentiation sec-
tions were further assessed by immunohistochemistry.
Immunohistochemistry
Pellet sections for immunohistochemical staining were
performed with a sequence of treatments as for the histo-
logical analysis. The sections were transfered onto glass
slides suitable for immunohistochemistry examination.
After deparaffinization and rehydration, we brought the
slides to a boil in 1 mM EDTA pH 8.0 followed by 8 mi-
nutes at a sub-boiling temperature and then allowed the
slides to cool at room temperature. The slides were rinsed
with deionized water three times. Endogenous peroxidase
activity was blocked by incubating sections in 3 % H2O2
solution in methanol at room temperature for 15 minutes.
The slides were rinsed with deionized water and
immersed with PBS for 5 minutes. Appropriately diluted
primary antibody (50–100 μl) was applied to the sections
on the slides and then they were incubated in a humidified
chamber at room temperature for 1 hour. The following
primary antibodies were applied: rabbit polyclonal anti-
bodies against collagen II (1:50, Abcam) or mouse mono-
clonal antibodies to collagen X (1:50, Abcam). The slides
were washed three times with PBS, 5 minutes each time.
The samples were then incubated with the corresponding
secondary antibodies (anti-rabbit and mouse; Roche) for
15 minutes at room temperature. The slides were further
washed three times with PBS, 5 minutes each time,
followed by DAB (Roche) detection under microscopy.
The slides were washed three times with PBS, 2 minutes
each time. The cell nuclei were counterstained by immers-
ing the slides in hematoxylin for about 1–2 minutes. De-
hydration was performed with graded ethanol series
followed by three consecutive steps of clarification with
xylene and the slides were finally mounted in Permount®
(Fisher) and visualized under a microscope. Negative
controls were processed following the same procedure
omitting the primary antibodies to exclude the level of
background staining.
Sulfated glycosaminoglycan content
Sulfated glycosaminoglycan (sGAG) content of chondro-
genic pellets was analyzed using the dimethylmethylene
blue (DMMB; Sigma) spectrophotometric method. Cells
or chondrogenic pellets were digested in 50 μl papain
solution (10 U/mL in PBS with 0.1 M sodium acetate,
2.4 mM EDTA, 5 mM L-cysteine; Sigma) at 60 °C for
2 hours. sGAG content in sample digest (50 μl) was
measured by mixing with DMMB dye solution (1 ml of
16 mg/l 1,9-dimethylmethylene blue, 40 mM glycine,
400 mM NaCl, pH 3.0) and measuring absorbance
(525 nm). The concentration of sGAG in each sample
was calculated against a standard curve of shark chon-
droitin sulfate (Sigma). DNA content was determined
using the Qubit dsDNA HS assay kit and Qubit
Fluorometer system (Invitrogen).
In vivo chondrogenesis study
Six-week-old SCID mice were intraperitoneally anesthe-
tized using avertin (1.25 %, Sigma). hiPSC–MSC-like
cells, which were chondrogenically induced for 10 days
in vitro, were implanted into the kidney capsule of the
mice. The specimens were harvested 6 weeks after im-
plantation. These specimens were fixed in 10 % neutral-
buffered formalin, dehydrated, clarified, and embedded
in paraffin. Sections were subjected to standard proce-
dures with alcian blue staining, toluidine blue staining
and collagen II and X immunochemical staining.
Real-time polymerase chain reaction analysis
Total RNA was extracted by TRIzol reagent (Invitrogen).
RNA was then converted into cDNA using the Reverse
Transcriptase System (Promega). cDNA samples were sub-
jected to real-time polymerase chain reaction (PCR) with
KAPA SYBR FAST qPCR kit Master Mix (2×) using a real-









CTTTTATGCCT. The 20 μl PCR systems contained 1 μl
cDNA template, SYBR Green qPCR Master Mix, 0.25 mM
forward primer and reverse primer. The reactions were in-
cubated in a 96-well plate at 95 °C for 10 minutes, followed
by 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute.
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All reactions were repeated three times. β-actin was used as
an internal control.
Statistical analysis
All quantitative data were collected independently at
least three times and yielded reproducible results. Data
are presented as the mean ± standard error of the mean
(SEM). Statistical analysis was performed using one-way
analysis of variance. Differences were considered statisti-
cally significant at P < 0.05.
Results
Generation of hiPSCs from peripheral blood
We generated hiPSCs by episomal reprogramming,
which was virus-free, nonintegrated and clinically rele-
vant. Human PBCs (Fig. 1a) were transfected with modi-
fied episomal vectors. About 13–14 days after
transfection, the human embryonic stem cell-like col-
onies (iPSC clones) became visible. On day 24, more
than 40 iPSC clones were observed. The iPSC clones
were then selected and harvested for expansion (Fig. 1b).
Most of the iPSCs were karyotypically normal (46,xy)
(Fig. 1c). The iPSC lines used in this research were
positive for the pluripotent markers OCT4, NANOG,
SSEA4, TRA-1-60 and TRA-1-81(Fig. 1d). Teratomas
were harvested over 2 months after the subcutaneous in-
jection of iPSCs into SCID mice. Histological examin-
ation showed that the teratoma contained various tissues
of the three germ layers (Fig. 1e).
Mesenchymal differentiation of hiPSCs
In order to differentiate the hiPSCs into the mesenchy-
mal lineage, we changed the culture medium of hiPSCs
into the differentiation medium, free of bFGF. A multi-
step culture method combining EB formation, mono-
layer culture and expansion were used as follows. First,
the iPSCs were spontaneously differentiated via EB for-
mation (Fig. 2a), followed by cell outgrowth from EBs on
gelatin-coated dishes. Typical iPSC morphology was
gradually lost and a spindle-shaped morphology at the
border of the colonies was formed (Fig. 2b). After 20 days
of differentiation, the cells were passaged with trypsin/
EDTA and the morphological change of the cells to a fi-
broblastic shape was observed after passage. The cells
were then cultured and expanded in monolayer after
subculture (Fig. 2c). The monolayer step was performed
Fig. 1 Generation of hiPSCs from peripheral blood. a Phase-contrast image of the PBCs. Scale bar = 100 μm. b Phase-contrast image of a hiPSC
line. Scale bar = 100 μm. c Karyotype (46,XY). d Fluorescent immunostaining of pluripotent markers OCT4, SSEA4, TRA-1-60, NANOG, and TRA-1-81.
Scale bars = 100 μm. e Teratoma formation. Teratomas were harvested over 2 months after subcutaneous injection of the iPSCs into SCID mice. (i)
Neuroepithelial cells, (ii) cartilage, and (iii) respiratory epithelium were detected by hematoxylin and eosin staining. Scale bar = 50 μm
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to exclude residual undifferentiated cells present in the
EBs as well as to expand cells committed to the mesen-
chymal lineage. The cells were seeded and cultivated in
monolayers for 5–7 days until cells reached about 90 %
confluence. Most cells were hiPSC–MSC-like cells. Fi-
nally a thre-dimensional pellet culture was utilized for
chondrocyte differentiation (Fig. 2d) [13].
Characterization of hiPSC–MSC-like cells
Before proceeding to pellet culture, the expression of cell
surface markers on hiPSC–MSC-like cells were analyzed.
Flow cytometric analysis demonstrated that the majority
of hiPSC–MSC-like cells expressed CD73 (81.81 ± 2.05 %)
and CD105 (endoglin) (81.90 ± 1.61 %), which are known
to be positive for human mesenchymal markers. CD34
and CD45, hematopoietic markers that are not expressed
in MSCs, were not detected in monolayer-cultured
hiPSC–MSC-like cells (Fig. 3). Expression of CD73,
CD105 and the lack of CD34 and CD45 suggested that
monolayer-cultured hiPSC–MSC-like cells may commit to
differentiating into mainly mesenchymal lineage cells. As a
comparison, we also detected the expression of CD73,
CD105, CD34, CD45, TRA-1-60 and SSEA4 of hiPSCs
(Additional file 1: Figure S1) and the expression of CD73,
CD105, CD34 and CD45 of hMSCs (Additional file 2:
Figure S2a). Almost all the hiPSCs expressed TRA-1-60
(94.8 ± 0.57 %) and SSEA4 (99.0 ± 0.12 %), and all the
hMSCs expressed CD73 (99.7 ± 0.63 %) and CD105
(98.7 ± 1.21 %). In order to avoid off-target effects, we
sorted pure MSCs (CD73 and CD105 double positive
cells) (Additional file 3: Figure S3) for chondrogenic
differentiation.
Morphological and histological characterization of
hiPSC–MSC chondrogenic pellets
After monolayer-cultured hiPSC–MSC-like cells were
dissociated into single cells, CD73+CD105+ cells were
sorted and cultured in 15-ml polypropylene tubes in pel-
lets for 21 days. Under these conditions, chondrogenic
cells are known to self-assemble in vitro into cartilagin-
ous tissue containing characteristic components of
extracellular matrix. In our experiments, dense cartilage-
like aggregates were observed. These aggregates were up
to 2–3 mm long and 3 mm thick (Fig. 2d). Paraffin sec-
tions of the aggregates were stained with alcian blue and
toluidine blue, which detected glycosaminoglycans and
proteoglycans typical of the cartilage extracellular matrix
(glycoprotein-rich matrix). The cell morphology and posi-
tive staining for alcian blue (Fig. 4a) and toluidine blue
(Fig. 4b) indicated the chondrogenic differentiation of
hiPSC–MSC pellets. The extracellular matrix of the
hiPSC–MSC chondrogenic pellets were further examined
Fig. 2 Generation of hiPSC–MSC-chondrogenic pellets via EB formation, monolayer cell culture and three-dimensional pellet culture. a EB formation.
Scale bar = 100 μm. b Cell outgrowth from EBs. Scale bar = 100 μm. c Monolayer cell culture. Scale bar = 100 μm. d Three-dimensional pellet culture
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for the staining of type II and X collagen by immuno-
histochemistry. Immunostaining positive for collagen
II (Fig. 4c) and collagen X (Fig. 4d) showed the
hiPSC–MSC chondrogenic pellets had developed a
chondrocyte-like phenotype. The negative control
(Additional file 4: Figure S4a) was shown to exclude
the level of background staining and better prove the
positive immunostaining.
After 21 days of chondrogenic induction, hMSCs also
formed dense cartilage-like aggregates (hMSC chondrogenic
pellets), which were 2–3 mm thick (Additional file 2:
Figure S2b) similar to the hiPSC–MSC chondrogenic pel-
lets. Paraffin sections of the aggregates were positively
stained with alcian blue and toluidine blue (Additional
file 2: Figure S2c,d). Compared to the negative control
(Additional file 4: Figure S4b), the immunochemistry re-
vealed that the pellets were surrounded by collagen II-
and X-positive extracellular matrix (Additional file 2:
Figure S2e,f ).
Biochemical analysis of hiPSC–MSC chondrogenic pellets
sGAG analysis was also performed after 21 days of chon-
drogenic differentiation (Fig. 4e). hiPSC–MSC chondro-
genic pellets were compared with hiPSC–MSC-like cells
and hMSC chondrogenic pellets, as well as the undifferen-
tiated hiPSCs and EBs. sGAG content was significantly in-
creased in hiPSC–MSC chondrogenic pellets compared to
hiPSC–MSC-like cells, as well as undifferentiated hiPSCs
and EBs (P < 0.05). As a comparison, the sGAG content of
hMSC chondrogenic pellets was also significantly higher
than hMSCs (P < 0.05), but was not significantly different
to hiPSC–MSC chondrogenic pellets.
In vivo chondrogenesis study
To determine the chondrogenic ability of hiPSC–MSC-
like cells to differentiate in vivo, we implanted hiPSC–
MSC-like cells into the kidney capsule of the SCID mice.
These in vitro differentiated cells continued to proliferate
and differentiate in vivo. The pellets were harvested
Fig. 3 Flow cytometric analysis of the MSC markers (CD73, CD105) and hematopoietic markers (CD34, CD45) in monolayer-cultured hiPSC–MSC-like
cells. a Immunological control for CD45, CD73. b Immunological control for CD34, CD105. c, d The cell surface markers CD34 and CD45 were not
expressed. e The proportion of CD73-expressing cells was 81.81 ± 2.05 %. f The proportion of CD105-expressing cells was 81.90 ± 1.61 %. Values
represent means ± SEM; n = 3. CD cluster of differentiation, Ig immunoglobulin
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6 weeks after transplantation. The morphology and
positive staining for alcian blue and toluidine blue, and
the staining of type II and X collagen-positive extracel-
lular matrix (Additional file 5: Figure S5) of the pellet,
indicated the chondrogenic differentiation of hiPSC–
MSC-like cells in vivo.
Gene expression of chondrogenic differentiation markers
in hiPSC–MSC chondrogenic pellets
The phenotype of chondrogenic pellets was further char-
acterized by assessing the relative expression of discrete
genes representative of the chondro-progenitor lineage
(SOX9 and COL2) and fully differentiated chondrocytes
(AGGRECAN and COL10) (Fig. 5). Transcript expres-
sions of AGGRECAN and COL10, the definitive markers
of differentiated chondrocytes, were more markedly in-
creased in the hiPSC–MSC chondrogenic pellets than in
hiPSCs and hiPSC–MSC-like cells (P < 0.05), which
further suggested a more advanced chondrogenic differen-
tiation. As a comparison, the markers for differentiated
chondrocytes in hMSC chondrogenic pellets were signifi-
cantly higher than in hMSCs (P < 0.05). These findings
comprehensively confirmed a successful approach to
exploiting chondrogenic differentiation via hiPSCs.
Discussion
Limited seed cell numbers remains a significant chal-
lenge for cartilage tissue regeneration. Scientists have
tried various cells sources for cartilage tissue repair. Pre-
vious studies showed that PBCs may be a good candi-
date for stem cell harvest, but inadequate information
on how to change or transform them into chondrocytes
still remains. In this study, we successfully transformed
PBCs into chondrocytes through an integration-free
method. Our findings suggested that, with appropriate
differentiation and purification protocols, human PBCs
Fig. 4 Characterization of hiPSC–MSC chondrogenic pellets. a Alcian blue staining and b toluidine blue staining of glycosaminoglycans and
proteoglycans revealed the chondrocyte-type appearance of the hiPSC–MSC chondrogenic pellets. Scale bars = 100 μm. c, d Immunohistochemistry
for type II and type X collagen. Scale bars = 100 μm. e Biochemical characterization of hiPSC–MSC chondrogenic pellets (hiPSC-Chon) versus hiPSCs,
EBs, hiPSC–MSC-like cells (hiPSC–MSCs) and hMSC chondrogenic pellets (hMSC-Chon) versus hMSCs. sGAG per DNA. Bars represent means ± SEM;
n = 3; *P< 0.05. EB embryoid body, hiPSC human induced pluripotent stem cell, hMSC human mesenchymal stem cell, sGAG sulfated glycosaminoglycan
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could be reprogrammed into iPSCs and further differen-
tiated into chondrogenic lineage in vitro. Similar to fi-
broblasts, four steps were taken after PBCs were
reprogrammed into iPSCs: (1) EB formation; (2) cell
outgrowth from EBs to increase cell number; (3) mono-
layer culture to remove undifferentiated cells and choose
cells that can follow MSC growth conditions; and (4)
three-dimensional pellet culture. When MSC-like cells
were generated, their surface markers were analyzed. The
results showed positivity for CD73 and CD105, and nega-
tivity for CD34 and CD45, similar to murine MSC induc-
tion from iPSCs [14]. In the consequent pellet culture
medium, transforming growth factor-beta1 and dexa-
methasone were supplemented. These factors have been
classically demonstrated to hold strong influence over the
chondrogenic potential ability [15].
MSCs are considered to be the current leading regen-
erative therapeutic cells for musculoskeletal diseases,
and various studies have been conducted. However,
there are still limiting factors such as heterogeneity, in-
sufficient cell numbers, and limited proliferative poten-
tial. Our study showed that the generation of iPSCs
from human PBCs may provide an alternative source of
MSCs for cartilage repair. Blood-derived iPSCs, which
have been proven to differentiate into MSCs, hepatocytes
and even cardiomyocytes, showed potential regenerative
abilities. Furthermore, PBCs may serve as an ideal source
for cellular reprogramming and cartilage tissue repair. As
peripheral blood is abundant and readily available, a good
amount of cells could be harvested from a given blood
volume. Additionally, PBCs do not require extensive cell
culture before they undergo reprogramming [16]. Now-
adays, peripheral blood application is common and is
widely used in the area of medical diagnostics and treat-
ment. Furthermore, large numbers of frozen blood sam-
ples are stored in biorepositories ready for use when
needed. Nucleated blood cells are essential cells in the
blood for reprogramming, including T lymphocytes, B
lymphocytes and other progenitor cells, while red blood
cells and platelets are depleted using lytic buffer treatment
often following multiple centrifugations, after which a
concentration of mononuclear cells can be obtained.
So far, viral and nonviral vector approaches have been
adopted for the generation of iPSCs. In early studies, viral
vectors were commonly used to convert blood CD34+ cells
into iPSCs due to their high-level reprogramming efficien-
cies [9]. However, several safety concerns, such as inser-
tional mutagenesis, tumor formation and differentiation
Fig. 5 Gene expressions of chondrogenic markers in hiPSC–MSC chondrogenic pellets. The expressions of COL2, COL10, SOX9 and AGGRECAN of
hiPSC–MSC chondrogenic pellets (hiPSC-Chon) versus hiPSCs and hiPSC–MSC-like cells (hiPSC–MSCs), compared with hMSC pellets (hMSC-Chon)
versus hMSCs. The expression levels of COL2, COL10, SOX9 and AGGRECAN were analyzed by real-time quantitative PCR relative to β-ACTIN. Bars
represent means ± SEM; n = 3; *P < 0.05. hiPSC human induced pluripotent stem cell, hMSC human mesenchymal stem cell
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process interruption, and so forth, have been previously
proposed [17, 18]. Therefore, integration-free iPSCs might
have the potential to eliminate the disadvantages associated
with integrating virus-associated genotoxicity and may be a
promising direction for clinical applications. Although
many techniques could be used to generate iPSCs from fi-
broblasts, there have been only two approaches so far re-
ported that could be employed and adopted in generating
blood-derived integration-free iPSCs: the sendai virus vec-
tor and episomal vector (EV) approaches. In this study, we
utilized EV, adopting the method of Su et al. [5]. EV seems
to be a cost-effective approach that requires no need for
viral vector packaging, and can be achieved by a single
infection.
The disadvantage associated with nonviral generation is
mostly reported to be the reprogramming efficiency. Okita
et al. [19] found that efficiency from mononuclear cells
could reach up to 0.1 % maximum, which suggested that
only a small volume of peripheral blood was sufficient for
the induction into iPSCs. They also found frozen cells
could further be utilized for the induction [19]. In this
study, the reprogramming efficiency in generating
integration-free iPSCs from blood cells was also satisfac-
tory and conserved. More than 40 iPSCs were easily gen-
erated from a 2 ml volume of peripheral blood, which was
adequate enough for this experiment. This is consistent
with the findings of Su et al. who demonstrated that about
20 to 30 iPSCs could be generated from a 1 ml peripheral
blood sample [5]. This is evidence that the nonviral
method is promising for future clinical applications.
Differentiation of iPSCs toward the chondrogenic
lineage is usually a complex process. In view of this,
classic chondrogenic medium was utilized for the induc-
tion of chondrogenesis from hiPSCs. In our study, the
specific matrix composition and the expression of se-
quential markers of chondrogenic differentiation indi-
cate successful induction. Transcript expressions of
AGGRECAN and COL10, the definitive markers of fully
differentiated chondrocytes, were also markedly in-
creased in the hiPSC–MSC chondrogenic pellets.
Our study found both chondrogenic gene expression
levels and sGAG production between hiPSC–MSC pellets
and hMSC pellets to be similar. Kang et al. also found that
hiPSC–MSCs have advanced proliferation capability and
adequate osteogenic and chondrogenic properties com-
pared to MSCs [20]. In vivo assay also indicated chondro-
genic differentiation of hiPSC–MSC-like cells. Our findings
suggested blood cell-derived hiPSC–MSCs possess a poten-
tial chondrogenic ability similar to bone marrow-derived
hMSCs.
In our study, collagen type X expression in both hiPSC–
MSC chondrogenic pellets and hMSC chondrogenic pellets
generated in vitro was weak, while aggrecan and collagen II
were robustly expressed. The low levels of collagen type X
staining in vitro were consistent with the hyaline cartilage
phenotype. Longer culture in vivo resulted in substantial
type X collagen staining, which is indicative of endochon-
dral progression. Pelttari et al. have reported that MSC pel-
lets with 4–7 week induction were also positive for type X
collagen [21], while chondrocytes from permanent articular
cartilage remain negative for collagen type X [22]. As
hiPSC–MSCs may possess similar chondrogenic ability to
hMSCs, it would also be expected that they would express
chondrogenic markers similarly.
Conclusions
In conclusion, this study proves that PBCs can be uti-
lized as candidates for regenerated chondrocytes. This
could reflect a future direction to generate seed cells for
cartilage repair in a patient-specific approach with cost-
effective applications in regenerative medicine.
Additional files
Additional file 1: Figure S1. Flow cytometric analysis of the
pluripotent markers (TRA-1-60, SSEA4), hematopoietic markers (CD34,
CD45) and MSC markers (CD73, CD105) in hiPSCs. The proportion of TRA-1-
60-expressing cells was 94.8 ± 0.57 %; The proportion of SSEA4-expressing
cells was 99.0 ± 0.12 %. Values represent means ± SEM; n = 3. (TIF 44 kb)
Additional file 2: Figure S2. Characterization of hMSCs and hMSC-
chondrogenic pellets. (a) Flow cytometric analysis of the hematopoietic
markers (CD34, CD45) and MSC markers (CD73, CD105) in hMSCs. The
proportion of CD73-expressing cells was 99.7 ± 0.63 %; The proportion of
CD105-expressing cells was 98.7 ± 1.21 %. Values represent means ± SEM;
n = 3. (b) Three-dimensional pellet culture of the hMSC-chondrogenic
pellet. (c) Alcian blue staining and (d) toluidine blue staining of
glycosaminoglycans and proteoglycans revealed the chondrocyte-type
appearance in the hMSC-chondrogenic pellets. Scale bar = 100 μm.
(e,f) Immunohistochemistry for type II and type X collagen. Scale
bar = 100 μm. (TIF 8130 kb)
Additional file 3: Figure S3. Flow cytometric analysis of the MSC
markers (CD73, CD105) on a single scatter plot. CD73 and CD105 double-
positive cells (about 70.2 %) were sorted for chondrogenic differentiation.
(TIF 731 kb)
Additional file 4: Figure S4. Negative controls of immunohistochemistry
for type II and type X collagen. The slides were performed omitting the
primary antibodies. As the secondary antibody is commonly used for
anti-rabbit and mouse, so the negative controls for collagen type II and
type X are the same. (a,b) Negative control for immunohistochemistry
of hiPSC–MSC chondrogenic pellets and hMSC chondrogenic pellets.
Scale bar = 100 μm. (TIF 8652 kb)
Additional file 5: Figure S5. Characterization of hiPSC–MSC
chondrogenic pellets cultured in vivo. (a) Alcian blue staining and (b)
toluidine blue staining of glycosaminoglycans and proteoglycans revealed
the chondrocyte-type appearance in the pellets. Scale bar = 100 μm. (c,d)
Immunohistochemistry for type II and type X collagen. Scale bar = 100 μm.
(TIF 7452 kb)
Abbreviations
bFGF: Basic fibroblast growth factor; DMEM: Dulbecco’s modified Eagle’s
medium; DMMB: Dimethylmethylene blue; EB: Embryoid body; EV: Episomal
vector; FBS: Fetal bovine serum; hiPSC: Human induced pluripotent stem cell;
hMSC: Human mesenchymal stem cell; IRB: Institutional Review Board;
KSR: Knockout serum replacement; MSC: Mesenchymal stem cell;
PBC: Peripheral blood cell; PBMNC: Peripheral blood mononuclear cell;
PBS: Phosphate-buffered saline; PCR: Polymerase chain reaction;
SEM: Standard error of the mean; sGAG: Sulfated glycosaminoglycan.
Li et al. Stem Cell Research & Therapy  (2016) 7:31 Page 10 of 11
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TL designed and performed the experiments, and drafted and revised the
manuscript. YL carried out the experiments and data analysis, and helped
draft the manuscript. NVH-L carried out language editing and performed
part of the experiments. JC performed part of the experiments. YL, NVH-L
and JC helped revise the manuscript critically for important intellectual
content. QS and YH provided technical support and revised and edited the
manuscript. All authors read and approved the final manuscript.
Acknowledgement
The authors wish to thank Xiaobin Zhang for his plasmid and Xi Xia for
human mesenchymal stem cells. We also thank Shaorong Gao and Qianfei
Wang for their kind help during the experiment. This study is supported by
National Natural Science Foundation of China (No.81101346, 81271963,
81100331) and Beijing 215 high level talent project (No.2014-3-025).
Author details
1Key Laboratory of Genomic and Precision Medicine, Beijing Institute of
Genomics, Chinese Academy of Sciences, Beijing 100101, China. 2Department
of Orthopedics, Beijing Chao-Yang Hospital, Capital Medical University,
GongTiNanLu 8#, Chaoyang District, Beijing 100020, China. 3Clinical and
Translational Research Center of Shanghai First Maternity & Infant Hospital,
School of Life Sciences and Technology, Tongji University, Shanghai, China.
Received: 31 July 2015 Revised: 31 January 2016
Accepted: 3 February 2016
References
1. Lee CR, Grodzinsky AJ, Hsu HP, Martin SD, Spector M. Effects of harvest
and selected cartilage repair procedures on the physical and biochemical
properties of articular cartilage in the canine knee. J Orthop Res. 2000;18(5):790–9.
doi:10.1002/jor.1100180517.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al.
Multilineage potential of adult human mesenchymal stem cells. Science.
1999;284(5411):143–7.
3. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S,
et al. Induced pluripotent stem cell lines derived from human somatic cells.
Science. 2007;318(5858):1917–20. doi:10.1126/science.1151526.
4. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al.
Induction of pluripotent stem cells from adult human fibroblasts by defined
factors. Cell. 2007;131(5):861–72. doi:10.1016/j.cell.2007.11.019.
5. Su RJ, Baylink DJ, Neises A, Kiroyan JB, Meng X, Payne KJ, et al. Efficient
generation of integration-free IPS cells from human adult peripheral blood
using BCL-XL together with Yamanaka factors. Plos ONE. 2013;8(5):e64496.
doi:10.1371/journal.pone.0064496.
6. Dowey SN, Huang X, Chou BK, Ye Z, Cheng L. Generation of integration-free
human induced pluripotent stem cells from postnatal blood mononuclear
cells by plasmid vector expression. Nat Protoc. 2012;7(11):2013–21.
doi:10.1038/nprot.2012.121.
7. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, et al.
Disease-specific induced pluripotent stem cells. Cell. 2008;134(5):877–86.
doi:10.1016/j.cell.2008.07.041.
8. Loh YH, Agarwal S, Park IH, Urbach A, Huo H, Heffner GC, et al. Generation of
induced pluripotent stem cells from human blood. Blood. 2009;113(22):5476–9.
doi:10.1182/blood-2009-02-204800.
9. Zhang XB. Cellular reprogramming of human peripheral blood cells. Genomics
Proteomics Bioinformatics. 2013;11(5):264–74. doi:10.1016/j.gpb.2013.09.001.
10. Pham TL, Nguyen TT, Van Bui A, Nguyen MT, Van Pham P. Fetal heart
extract facilitates the differentiation of human umbilical cord blood-derived
mesenchymal stem cells into heart muscle precursor cells. Cytotechnology.
2014;1-14. doi:10.1007/s10616-014-9812-2.
11. Stecklum M, Wulf-Goldenberg A, Purfurst B, Siegert A, Keil M, Eckert K, et al.
Cell differentiation mediated by co-culture of human umbilical cord
blood stem cells with murine hepatic cells. In Vitro Cell Dev Biol Anim.
2015;51(2):183–91. doi:10.1007/s11626-014-9817-3.
12. Xia X, Ji T, Chen P, Li X, Fang Y, Gao Q, et al. Mesenchymal stem
cells as carriers and amplifiers in CRAd delivery to tumors. Mol Cancer.
2011;10:134. doi:10.1186/1476-4598-10-134.
13. Koyama N, Miura M, Nakao K, Kondo E, Fujii T, Taura D, et al. Human
induced pluripotent stem cells differentiated into chondrogenic lineage via
generation of mesenchymal progenitor cells. Stem Cells Dev. 2013;22(1):
102–13. doi:10.1089/scd.2012.0127.
14. Teramura T, Onodera Y, Mihara T, Hosoi Y, Hamanishi C, Fukuda K. Induction
of mesenchymal progenitor cells with chondrogenic property from mouse-
induced pluripotent stem cells. Cell Reprogram. 2010;12(3):249–61. doi:10.
1089/cell.2009.0086.
15. Awad HA, Halvorsen YD, Gimble JM, Guilak F. Effects of transforming
growth factor beta1 and dexamethasone on the growth and chondrogenic
differentiation of adipose-derived stromal cells. Tissue Eng. 2003;9(6):1301–12.
doi:10.1089/10763270360728215.
16. Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, Sommer CA, et al.
Reprogramming of human peripheral blood cells to induced pluripotent
stem cells. Cell Stem Cell. 2010;7(1):20–4. doi:10.1016/j.stem.2010.06.002.
17. Sommer CA, Sommer AG, Longmire TA, Christodoulou C, Thomas DD,
Gostissa M, et al. Excision of reprogramming transgenes improves the
differentiation potential of iPS cells generated with a single excisable
vector. Stem Cells. 2010;28(1):64–74. doi:10.1002/stem.255.
18. Carey BW, Markoulaki S, Hanna JH, Faddah DA, Buganim Y, Kim J, et al.
Reprogramming factor stoichiometry influences the epigenetic state and
biological properties of induced pluripotent stem cells. Cell Stem Cell.
2011;9(6):588–98. doi:10.1016/j.stem.2011.11.003.
19. Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, et al.
An efficient nonviral method to generate integration-free human-induced
pluripotent stem cells from cord blood and peripheral blood cells. Stem
Cells. 2013;31(3):458–66. doi:10.1002/stem.1293.
20. Kang R, Zhou Y, Tan S, Zhou G, Aagaard L, Xie L, et al. Mesenchymal stem
cells derived from human induced pluripotent stem cells retain adequate
osteogenicity and chondrogenicity but less adipogenicity. Stem Cell Res
Ther. 2015;6:144. doi:10.1186/s13287-015-0137-7.
21. Pelttari K, Winter A, Steck E, Goetzke K, Hennig T, Ochs BG, et al. Premature
induction of hypertrophy during in vitro chondrogenesis of human
mesenchymal stem cells correlates with calcification and vascular invasion
after ectopic transplantation in SCID mice. Arthritis Rheum. 2006;54(10):
3254–66. doi:10.1002/art.22136.
22. Dickhut A, Pelttari K, Janicki P, Wagner W, Eckstein V, Egermann M, et al.
Calcification or dedifferentiation: requirement to lock mesenchymal stem
cells in a desired differentiation stage. J Cell Physiol. 2009;219(1):219–26.
doi:10.1002/jcp.21673.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li et al. Stem Cell Research & Therapy  (2016) 7:31 Page 11 of 11
